SARS-CoV-2 nsp13-IN-7
SARS-CoV-2 nsp13-IN-7 (Compound 6r) is a SARS-CoV-2 nsp13 inhibitor (IC50: 0.28 μM) . SARS-CoV-2 nsp13-IN-7 interferes with the helicase function of nsp13 by binding to the 5' RNA site and ATP binding site of nsp13. SARS-CoV-2 nsp13-IN-7 can be used as a lead compound for the development of antiviral drugs targeting SARS-CoV-2 nsp13[1].
Product Specifications
UNSPSC
12352005
Target
SARS-CoV
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(N/N=C/C1=C(Cl)C=CC([N+]([O-])=O)=C1)C(C=C2)=CC=C2CSC3=CC=CC4=CC=CN=C43
Molecular Formula
C24H17ClN4O3S
Molecular Weight
476.93
References & Citations
[1]Fan D, et al. Discovery of 4- ((quinolin-8-ylthio) methyl) benzamide derivatives as a new class of SARS-CoV-2 nsp13 inhibitors. Bioorg Med Chem Lett. 2025 Jul 1;122:130207.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470053-100 1x 100 µL
HCG-alpha (HCGa/53), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472250-100 1x 100 µL
Squamous Cell Carcinoma Antigen 1 (CPTC-SERPINB3-2), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details